Accessibility Menu
Pfizer logo

Pfizer(FRA) PFE

Market Cap€132.55BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1998)+97%
5 Year-45%
1 Year+9%
1 Month+6%
€23.71
+0.70%
+0.17Today
Pfizer last closing stock price
MetricPriceDate
Last closeEUR 23.492026-08-18
Pfizer stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.86%EUR 23.062026-08-11
1 month+6.24%EUR 22.112026-07-17
3 month+6.15%EUR 22.132026-05-20
Year to date+10.44%EUR 21.272025-12-30
1 year+8.85%EUR 21.582025-08-18
3 year-30.4%EUR 33.752023-08-18
5 year-44.6%EUR 42.402021-08-19
Since inception+97.23%EUR 11.791998-04-29

Pfizer Financials at a Glance

Market Cap

€132.55BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$63.64B

Net Income (TTM)

$4.32B

EPS (TTM)

€0.64

P/E Ratio

36.08

Dividend

€1.48

Beta (Volatility)

-0.05 (Low)

Price

€23.71

Volume

1,372

Open

€23.45

Previous Close

€23.55

Daily Range

€23.45 - €23.71

52-Week Range

€20.13 - €24.86

Estimated Earnings Date

Nov 3, 2026

PFE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pfizer

Pfizer Inc. operates as a global biopharmaceutical enterprise, dedicated to the discovery, development, production, marketing, and distribution of a wide array of medicinal and vaccine products across the globe. Its extensive portfolio addresses numerous therapeutic areas, including treatments for cardiovascular, metabolic, and women's health conditions.

Products and Services
  • Medicinal products for various therapeutic areas
  • Vaccines for major diseases, including COVID-19
  • Contract manufacturing services for pharmaceuticals
Growth Outlook
  • Recent quarterly revenue of €15.03 billion shows strong market demand
  • Continued investment in R&D, with €2.81 billion allocated last quarter
  • Strategic collaborations with industry leaders enhance product pipeline
Financial Highlights
  • Trailing twelve-month revenue of €59.5 billion reflects solid performance
  • Net income margin of 6.8% indicates profitability despite challenges
  • Dividend yield of 6.54% offers attractive returns to investors
Pfizer Inc. has established itself as a leader in the biopharmaceutical industry, with a diverse product portfolio that includes both innovative medicines and vaccines. The company's commitment to research and development is evident in its significant investment, which aims to address unmet medical needs and expand its therapeutic offerings. Recent financial performance highlights a robust revenue stream, driven by strong demand for its products, particularly in the wake of the COVID-19 pandemic. The company's strategic partnerships further bolster its growth potential, positioning it well for future success. With a solid dividend yield, Pfizer presents an appealing option for investors seeking exposure to the healthcare sector.
AI Generated • Aug 12, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

75,000

CEO

Albert Bourla, PhD, DVM

Website

www.pfizer.com

Headquarters

New York City, NY 10017, US

PFE Financials

Key Financial Metrics (TTM)

Gross Margin

71.32%

Operating Margin

25.08%

Net Income Margin

6.81%

Return on Equity

4.89%

Return on Capital

11.15%

Return on Assets

2.16%

Earnings Yield

2.77%

Dividend Yield

6.37%

Payout Ratio

2.26%

Stock Overview

Market Cap

€132.55BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

5.70B

Volume

1.37K

Avg. Volume

7.78K

Financials (TTM)

Gross Profit

$45.31B

Operating Income

$16.99B

EBITDA

$18.21B

Operating Cash Flow

$13.40B

Capital Expenditure

-$2.42B

Free Cash Flow

$10.99B

Cash & ST Invst.

$11.70B

Total Debt

$63.19B

Pfizer Performance Analysis

Pfizer annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 95,463,798,12938.8%
20232023-12-31USD 55,084,765,991-42.3%
20242024-12-31USD 58,821,802,4686.8%
20252025-12-31USD 55,449,426,393-5.7%
Pfizer sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-2813.7%
Q42025-12-315.4%
Q12026-03-31-18.0%
Q22026-06-304.4%
Pfizer annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 5.2158.6%
20232023-12-31USD 0.35-93.4%
20242024-12-31USD 1.30276.2%
20252025-12-31USD 1.20-7.6%
Pfizer sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-2821.6%
Q42025-12-31-146.8%
Q12026-03-31262.1%
Q22026-06-30-108.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$15.03B

+2.6%

Gross Profit

$10.94B

+0.6%

Gross Margin

72.78%

N/A

Market Cap

€132.55BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

€1.77M

N/A

Employees

75,000

N/A

Net Income

-$248.00M

-108.5%

EBITDA

$1.64B

-69.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$11.70B

-11.7%

Total Debt

$63.19B

+3.7%

Accounts Receivable

$16.19B

+0.6%

Inventory

$9.95B

-14.8%

Long Term Debt

$60.50B

+6.8%

Short Term Debt

$2.70B

-37.2%

Return on Assets

2.16%

N/A

Return on Invested Capital

9.48%

N/A

Free Cash Flow

$302.00M

+125.2%

Operating Cash Flow

$835.00M

+243.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,701.85-0.01%
^DJIDJI
$53,396.81-0.00%
^IXICNASDAQ
$26,314.93-0.01%
BTCBitcoin
$64,721.00+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
KORUDirexion Shares ETF Trust - Direxion Daily Msci South Korea Bull 3x Shares
$17.84-0.24%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$44.19+0.15%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$129.10-0.15%
NOKNokia
$10.39-0.04%

Questions About PFE

What is the current price of Pfizer?

Pfizer is trading at €23.71 per share.

What is the 52-week range for Pfizer?

Over the past 52 weeks, Pfizer has traded between €20.13 and €24.86.

How much debt does Pfizer have?

As of the most recent reporting period, Pfizer reported total debt of $55.27B.

How much cash does Pfizer have on hand?

Pfizer reported $853.67M in cash and cash equivalents in its most recent financial results.

What is Pfizer’s dividend yield?

Pfizer currently has a dividend yield of 6.37%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services